Macerich Company (The) Common Stock vs Sanofi SA — how do they compare? Macerich Company (The) Common Stock trades at $22.48 (market cap $6.29B), while Sanofi SA trades at $40.64 (market cap $96.38B). The key difference: Sanofi SA is far larger — about 15.3× Macerich Company (The) Common Stock's market cap, and Sanofi SA pays the higher dividend (6.08%). Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| MAC | SNY | |
|---|---|---|
Market Cap | $6.29B | $96.38B |
Volume | 3,158,142 | 5,335,342 |
Sector | Real Estate | Health |
52-Week High | $26.51 | $52.34 |
52-Week Low | $16.20 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $10.97B | $115.67B |
Dividend Yield | 3.07% | 6.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNY trades at $39.12, down 1.56% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, potentially driving future growth. Analyst consensus is mixed, with 44% buy ratings but a majority hold stance.
The outlook is cautiously optimistic, supported by earnings beats and strategic partnerships, but risks include a projected net income decline in 2026 and competitive pressures. The stock's current valuation metrics, such as a P/E of 22.06, appear reasonable relative to historical performance, though investor sentiment remains tempered by near-term challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →